United States: In Re: Accutane

On the Basis of the Learned Intermediary Doctrine, New Jersey Superior Court Dismissed 160 of 162 Plaintiffs in the Accutane MDL

On October 12, 2016, in two separate orders, the New Jersey Superior Court overseeing the In re Accutane Litigation mass coordinated litigation dismissed 160 of the 162 remaining plaintiffs on the basis of the learned intermediary doctrine ("LID").37

As discussed in our Products Liability & Toxic Torts Spring 2016 Alert, in January 2016, the Court — after discussing the six public policy elements that support the LID — held that "[i]n prescription drug cases where the LID applies, it is the physician who is viewed as the user" and that, in such cases, "[t]he intended 'audience' of the labeling and warnings are medical doctors, not patients."38 The Court asked the parties for additional briefing on how the Court's ruling applied to out-of-state plaintiffs.

The Court dismissed 86 plaintiffs in its first October 2016 order, holding that they failed to satisfy their burden of proof because their physicians had either died or had not been located.39 While the plaintiffs argued that the Court should apply the "heeding presumption," under which "there is a rebuttable presumption that the recipient of an adequate warning in a failure-to-warn case would have heeded the warning,"40 the Court disagreed. Specifically, the Court found that the plaintiffs' "reasoning is flawed" because if the Court denied the defendants' motion for summary judgment,"[p]laintiffs' claims would go before a jury with testimony from [p]laintiff that she/ he ingested Accutane [with] no testimony from the prescribing physician[,] [and] [t]he jurors would be left to speculate as to what the prescribing physician considered of the warning(s)."41 Importantly, the Court noted that if a heeding presumption were applied to prescription drugs, "given that every prescription medication has associated risks, heeding those warnings would result in medications never being prescribed. While that may be Plaintiffs' counsels' hopes, it is not reality."42 Additionally, because the Court found it was unreasonable to believe that prescribing physicians would "cease to prescribe" Accutane,43 the Court held that, under New Jersey law, "[n]either policy nor reason warrant the extension of the heeding presumption to these cases."44 While the Court, citing its July 24, 2015 order, noted that New Jersey's proximate cause standard applied and dismissed the applicable plaintiffs under that standard, the Court nonetheless reviewed the proximate cause standard of outof- state plaintiffs from 19 and found the plaintiffs would be dismissed under those jurisdictions as well.45

In the second order, noting that the plaintiffs' counsel had "done their best to conflate the LID with the informed consent doctrine," the Court held that that was "simply not the law" and that "[w]hen a prescribing physician comprehends the fact that a given medicine is associated with certain potential risks, and exercises his/her medical judgment in deciding whether and how to address those risks with his/her patient, the manufacturer cannot be held responsible for the prescriber's decision."46 The Court found that the law in 15 states was consistent with New Jersey's LID statute and, on individual bases, dismissed the applicable plaintiffs when the defendants met their LID burden.47

The Court's orders demonstrate well considered arguments on the heeding presumption and the difference between the LID and the informed consent doctrine. Because of the growing application of the LID, plaintiffs continue to seek ways to bypass it. The New Jersey Superior Court saw past the plaintiffs' attempts on both counts. That said, these decisions do not mean defendants can rest easy – Defendants in mass tort cases will have their work cut out for them to depose the medical professionals (who are available). Indeed, as to the two remaining cases, the Court found that (1) the prescriber's testimony "demonstrate[d] substantial uncertainty" about whether a different warning would have changed the prescriber's decision and (2) the prescriber testified that he was "not sure" if he would have changed his decision based on a different warning. As such, defendants must be prepared to effectively challenge prescribers at deposition about whether he/she would have made a different decision with a different warning.

Footnotes

37. No. 271, 2016 WL 5958374 (N.J. Super. Ct. Law Div. Oct. 12, 2016); 2016 WL 5958375 (N. J. Super. Law Div. Oct. 12, 2016).

38.  In re Accutane Litigation, No. 271, 2016 WL 355843, at *4 (N.J. Super. Law Div. Jan. 29, 2016). The six elements discussed by the Court were that "(1) Prescription medications require far more precaution than an over-the-counter ("OTC") drug . . . (2) Prescription drugs are often complex medications . . . (3) . . . with a prescription drug, it is inconceivable that a manufacturer could fulfill its obligation of a warning sufficiently understandable by the average person . . . (4) The treating physician plays the role of the go-between to the full extent implied by that term . . . ." (5) patients would be unlikely to properly evaluate technical information; and "(6) Human nature is what it is, the common law acknowledges that, after the fact, upon diagnosis of a condition said to be associated with a medication, that the patient is likely to testify that she/he would never have taken the medication had they known then, what they know now." (Id.).

39.  2016 WL 5958374 at *3.

40. Id. at *4 (citing Coffman v. Keene Corp., 628 A.2d 710, 720-21 (N.J. 1993)).

41. Id. at *11.

42.  Id.

43.  Id. ("(1) the medical community issued statements urging continued use, (2) there is evidence that the learned intermediaries were otherwise aware of the risk of IBD, and (3) no evidence has been provided supporting the notion that one additional risk factor would lead the prescribing physicians to avoid this drug. Additionally, this is not a no-warning case. All prescribing physicians were aware of at least a risk of 'temporal association' with IBD. Sufficient evidence has been presented to rebut the heeding presumption, were it to apply in any of these cases.").

44.  Id. at *12.

45.  Id. at * 12-16.

46.  2016 WL 5958375, at *5. Here, the Court, found "[c]oursing through the deposition testimony. . . facts and instances revealing the 'condition' in which many Plaintiffs' [sic] found themselves prior to being prescribed Accutane . . . . In truth, Accutane was their only hope for relief . . . . It was prescribed as a last measure of treatment; many Plaintiffs were impatient to receive it." Id. at *6.

47. Id. at *8-48. Depending on the individual, the Court found the defendants had established that the LID applied because the prescriber: (1) was aware of the risk, (2) had not read the warning at all, (3) judged the risk was not severe, (4) affirmatively decided not to warn the patient, or (5) would not have changed his/her decision based on the information he/she subsequently learned.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.